CDKN2A and anaplastic astrocytoma: Delaying treatment to wait for the molecular analysis (for instance IDH1-2 mutations results) could be detrimental for the patient, especially when the prognostic role of IDH1-2 status in HGG is debated, as described in recent studies which propose CDKN2A/B for anaplastic astrocytoma [17–19].